(Credit-Canva)
We all enjoy a good slushie every now and then. While they do not add any great nutritional value to our meal, they are a delightful snack made with shredded ice and sugar. To make them more accessible to people who cannot or do not wish to have sugar, there are many sugar free options to pick from. However, a recent study has revealed that sugar-free slushies containing glycerol, which is a sugar alcohol used to maintain their icy texture, can cause severe health problems in young children. The study was published in the journal Archives of Disease in Childhood, it explains that having these sugar free slushies can lead to children having a condition called "glycerol intoxication syndrome". In this condition there is a rapid drop in blood sugar, reduced consciousness, and a buildup of acid in the blood.
Kids who drank slushies with glycerol got sick very quickly. Within an hour, they started showing serious symptoms. Their blood sugar would plummet, sometimes dangerously low. Many became confused or lost consciousness, and some even had seizures. Doctors studied 21 children who got sick from these drinks between 2018 and 2024. Most of these kids were very young, seven years old or younger. By the time they got to the hospital, many were in bad shape, either unconscious or barely awake. This quick reaction time makes it especially scary, as parents might not realize the slushy is the cause right away. It's important to recognize these signs fast.
According to WebMD Glycerol is a type of naturally occurring alcohol, and it's used in lots of food products. You might find it in protein bars, diet foods, and even sugar-free candies. In slushies, it plays a key role in keeping the drink icy. Usually, slushies use tons of sugar to stop them from freezing completely. But because people are trying to cut back on sugar, companies are using glycerol instead. This is especially true in places with "sugar taxes," where sugary drinks cost more. So, to make sugar-free versions, they add glycerol. This switch means more kids are being exposed to this ingredient, which can be harmful to them.
The study explains that little kids are more at risk from glycerol because their bodies are still growing and developing. Their tiny bodies and young metabolisms might not be able to handle glycerol as well as adults' bodies can. This means that even a small amount can cause a big problem. Also, the amount of glycerol in a slushy can vary, and it's hard to know exactly how much is safe. Factors like how fast they drink it, if they've eaten recently, or if they've been exercising can also make a difference. Even the standard size of a slushy drink can be too much for a small child. This makes it hard to give a safe dose.
Health authorities in the UK and Ireland have already started warning about glycerol in slushies. They suggest that kids under four shouldn't have them at all, and older kids should only have one at most. But doctors are worried that these warnings might not be enough. They point out that it's hard to know how much glycerol is actually in each drink, making it difficult to give safe advice. Parents are being told to be very careful and consider avoiding these drinks altogether for young children. In the US, glycerol is approved for use in food, but parents should still be aware of the potential risks. More research is needed to understand the full impact.
Credits: iStock
Can a simple test detect multiple cancer all at once? The New York Times reports that in the spring of 2021, this idea had first came into being, where a simple test could detect different cancer including those that do not have any regular screening. Now, the buzz is even louder around that. The test is called Galleri, and data suggest that its performance has improved.
Many companies are racing to develop this multi-cancer early-detection blood test and while none are yet approved by the federal regulators, people are already demanding for it. They cost hundreds of dollars.
The company that manufactures Galleri, GRAIL, said that a total of 420,000 tests had been prescribed so far, which shows a surge from 180,000 as of March 31, 2024. The company is also planning to apply for approval from the Food and Drug Administration (FDA), next year. It is also seeking that Medicare would cover the tests.
While the demand is there, the research on it is limited. Cristian Tomasetti, the director of the Center for Cancer Prevention, Early Detection and Monitoring at City of Hope, a cancer center in Southern California told the NYT, "It feels like the airplane is being built while flying."
Most of the available evidence so far comes from studies conducted by GRAIL and other test developers. In GRAIL’s latest study, nearly 99 percent of the around 23,000 people screened using the Galleri test received a negative result. However, 40 percent of positive findings were later found to be false, and the test detected only 40 percent of cancers that were diagnosed within a year, missing the remaining 60 percent.
The idea behind this test is that when cancer is detected earlier, it is easier to treat. Dr. Elizabeth O’Donnell, who heads a multi-cancer early detection clinic at Dana-Farber Cancer Institute in Boston described the experience as doing something truly meaningful for a patient, particularly when the cancer involved has no established screening test.
That possibility became real for William Hill, a 56-year-old firefighter from Brockton, Massachusetts, who took the Galleri blood test last year during a firefighters’ conference. Firefighters are often exposed to carcinogens while on duty. His blood sample was sent to a North Carolina laboratory, where scientists analyzed fragments of DNA for patterns that could indicate cancer and identify its likely origin.
Two weeks later, the result came back: a cancer signal had been detected.
Hill said he initially hoped the finding was a mistake, especially since he had already been treated for testicular cancer in the past. Further testing at Dana-Farber, including an abdominal CT scan, confirmed metastatic testicular cancer, and treatment began right away.
Looking back, Hill realized that symptoms he had brushed off, such as back pain and frequent urination, were caused by a tumor pressing against his kidney. At the time, he had attributed them to aging and the physical demands of his job.
While it remains unclear whether the test ultimately changed his long-term prognosis, Hill believes it prompted earlier treatment. He said that without the test, he likely would not have suspected cancer and might have delayed care, allowing the tumor to grow further.
Stories like Hill’s point to the promise of multi-cancer blood tests. However, there is still no solid evidence that they reduce cancer-related deaths. Such proof exists for screenings like breast, cervical, colon, and lung cancer, based on large randomized trials conducted over many years.
Credits: Canva
Weight-loss jabs, or GLP-1 receptor agonists, have provided many people with results that diets alone could not achieve. For those struggling with constant cravings, these medications have quieted the persistent “food noise” that often drives overeating. They have transformed not only body shapes but also self-confidence and daily habits.
Yet questions remain: can people safely stop taking these drugs, and what happens to the body when they do? These are still largely unknown, as the drugs are relatively new. GLP-1s mimic a natural hormone that controls hunger, but the long-term effects are only beginning to be understood. Additionally, for the estimated 1.5 million people in the UK paying privately for these injections, maintaining treatment can be costly.
Two women, Tanya and Ellen, share their personal experiences with the BBC on weight-loss jabs and what life was like when they attempted to stop.
Tanya, a sales manager in the fitness industry, initially started taking Wegovy to challenge her own perceptions about weight and authority. She often felt overlooked or undervalued because of her size, and hoped that losing weight would change how others treated her, as per BBC.
Early in treatment, Tanya experienced side effects including nausea, headaches, sleep issues, and hair loss, which she describes as clumps coming out. Despite this, she steadily lost weight—six stone (38 kg) over 18 months—and the injections quieted the relentless urge to eat.
However, every time she tried to stop, her appetite surged within days, leaving her horrified at her own eating. Now, Tanya continues the medication, feeling it has become essential to maintaining her weight and the confidence it brings.
Wegovy’s manufacturer, Novo Nordisk, stresses that treatment decisions should be made with medical guidance and that side effects must be considered. Lifestyle GP Dr. Hussain Al-Zubaidi likens stopping GLP-1s abruptly to being hit by a “tsunami” of hunger.
Research shows that within one to three years of stopping these medications, people can regain 60–80% of the weight they lost. This highlights how these drugs work not just by reducing appetite temporarily but by fundamentally altering hunger cues.
Ellen turned to Mounjaro after reaching a critical point in her life. Her weight had put her at risk during surgery, and emotional binge eating dominated her daily habits. Once on the medication, Ellen noticed her compulsive eating completely stopped.
Over 16 weeks, she lost 3 st 7 lb (22 kg) and began tapering off the injections over six weeks. She focused on developing a healthier relationship with food, creating balanced meals, and incorporating exercise into her routine. Despite some weight creep after stopping, she has since lost a total of 51 kg and now feels confident her habits are sustainable.
Dr. Al-Zubaidi emphasizes that exiting GLP-1 treatment safely requires guidance and long-term support. NICE recommends at least a year of tailored advice after stopping injections to help individuals maintain their weight and prevent relapse, as per BBC.
For patients paying privately, such structured support may not always be available, increasing the risk of regaining weight. Lifestyle, mindset, and environmental factors play a significant role in long-term outcomes.
Tanya has chosen to continue with her medication, aware of the pros and cons, while Ellen has closed that chapter and built a sustainable routine for life after Mounjaro.
Weight-loss jabs can dramatically change appetite and body weight, but stopping them can be challenging. The transition off these drugs requires careful planning, support, and lifestyle adjustments. As Tanya and Ellen’s experiences show, the journey varies by individual, and long-term strategies are essential to maintaining health and weight loss results.
Eli Lilly, the manufacturer of Mounjaro, states that patient safety is its top priority and that it continually monitors and reports information on treatment outcomes to regulators and prescribers.
Credits: Canva
Flu Symptoms: Seasonal infections are spreading across the United States just as the holiday travel rush gets underway, worrying health officials about fresh spikes during family get-togethers. Flu and norovirus cases are rising in several states, while COVID-19 continues to circulate at lower but consistent levels. Together, these illnesses are adding strain on hospitals as millions of people plan to travel in the days ahead.
“Super flu” is not a clinical term, but it is often used to describe a flu season that feels more aggressive or spreads faster than usual. This is typically linked to a dominant strain of influenza A. The current surge is being driven by a mutated influenza A strain known as H3N2 subclade K. Health officials say this strain has become the leading flu variant in the US, accounting for roughly 89 percent of H3N2 samples analysed since late September, according to genetic sequencing data from the Centers for Disease Control and Prevention (CDC).
This variant emerged after the 2025–26 flu vaccine was formulated, meaning the vaccine may not be as closely matched as in earlier seasons. While the shot still offers protection against severe disease, experts note that the mismatch could allow the virus to spread more easily.
The symptoms seen in the current flu wave are largely familiar. People may develop fever, chills, extreme tiredness, cough, and body aches. Doctors, however, caution that the wider spread could result in more serious cases, particularly among people who are at higher risk.
CDC estimates indicate that the US has already seen about 4.6 million flu cases this season, along with nearly 49,000 hospital admissions and around 1,900 deaths. Flu activity increased sharply in mid-December, with test positivity jumping from 8.1 percent to 14.3 percent within a single week.
Doctors recommend staying home when feeling unwell, washing hands often, especially to limit norovirus spread, and considering vaccination against flu and COVID-19. Even when the strain match is not ideal, experts stress that vaccines remain crucial in reducing the risk of severe illness, hospitalisation, and death.
In terms of how easily it spreads, it behaves much like regular flu, which is known to be highly contagious.
Someone with flu can pass on the virus from around one day before symptoms appear and continue to be contagious for five to seven days after becoming sick. Children, older adults, and those with weakened immune systems may remain infectious for a longer period.
The virus mainly spreads through respiratory droplets released when an infected person coughs, sneezes, speaks, or breathes near others. It can also spread through contact with contaminated surfaces, followed by touching the mouth, nose, or eyes. Crowded indoor settings, poor airflow, and close contact make transmission far more likely, which explains why flu spreads quickly during peak season.
What makes a so-called “super flu” seem more contagious is not a new way of spreading, but higher case numbers, quicker community transmission, and stronger symptoms, all of which increase coughing, fever, and the amount of virus released.
© 2024 Bennett, Coleman & Company Limited